Global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio
Breelib™ meets iloprost
A modern nebuliser for an established drug.
A large and untapped US market with few new entrants into this complex space.
New product creation – from paper to market
We take products from a blank piece of paper right the way through to market, but the patient is always at the centre of what we do.
Bringing nebuliser device and formulation together
Our unique capabilities mean "all the pieces of the jigsaw fit".
Fundraising for AsthmaUK
Vectura deploys its international pedal power for charity.
Vectura Group Interim Results for H1 2018
Rising to the challenge of developing inhaled generic medicines
And why Vectura is well placed to innovate in this space.
Pre-close trading update confirms good progress against 2018 goals
The Group expects revenue to be in line with, and EBITDA to be materially above, current market consensus expectations.